Welcome to our dedicated page for Vivopower International Plc news (Ticker: VIVO), a resource for investors and traders seeking the latest updates and insights on Vivopower International Plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vivopower International Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vivopower International Plc's position in the market.
Meridian Bioscience announced the appointment of Andy Kitzmiller as the new Chief Financial Officer on February 21, 2022. Kitzmiller will report directly to CEO Jack Kenny and will manage all financial functions including accounting, financial planning, and treasury. Previously, he served as Vice President at Hillenbrand, Inc., and has extensive experience in finance roles at Milacron and GE Aviation. Kenny expressed optimism about Kitzmiller's strategic finance expertise to drive sustainable growth.
Meridian Bioscience (NASDAQ: VIVO) announced the resumption of manufacturing and distribution of its LeadCare II test kits after a temporary halt due to discrepancies identified in the kits' performance. The issue was traced to the paperboard packaging material, which potentially underestimated blood lead levels. Following extensive studies, suitable replacement materials have been identified to rectify the issue. Executive VP Tony Serafini-Lamanna emphasized the importance of LeadCare II in diagnosing childhood lead exposure.
Meridian Bioscience, Inc. (NASDAQ: VIVO) reported first-quarter fiscal 2022 revenues of $88.3 million, only 5% below last year's record results. The Diagnostics segment grew 10% year-over-year to $33.2 million, while Life Science revenues declined 12% to $55.1 million. Operating income was $20.3 million with a margin of 23%. Meridian raised its fiscal 2022 revenue guidance to $315-$330 million, driven by strong demand in both segments despite ongoing COVID-19 challenges. Cash at quarter-end was $72.7 million.
Meridian Bioscience (NASDAQ: VIVO) has secured an additional $2.5M funding from the NIH's RADx initiative, supplementing an existing $5.5M award. This funding aims to enhance the research, development, and production of the Revogene® molecular viral respiratory diagnostic testing panel, which detects SARS-CoV-2, RSV, and influenza A/B. The investment will facilitate improvements in manufacturing efficiency to meet rising demand for accurate respiratory testing as COVID-19 transitions to an endemic phase. Meridian emphasizes the critical role of this testing in providing timely patient care.
Meridian Bioscience, a leader in diagnostic testing, has launched two new master mixes: Lyo-Ready™ Direct DNA qPCR Saliva Mix and Lyo-Ready™ Direct RNA/DNA qPCR Saliva Mix. These mixes enhance the detection of DNA and RNA in crude saliva samples, improving assay sensitivity and simplifying protocols. Designed for use in both liquid and lyophilized formats, they address challenges posed by PCR inhibitors in saliva. This launch comes at a critical time with rising respiratory infections, making saliva testing more urgent. Meridian aims to lead in innovative diagnostic solutions.
Meridian Bioscience (NASDAQ: VIVO) has announced the election of John C. McIlwraith as Chairman of the Board, effective January 26, 2022, succeeding David C. Phillips who retired after over 21 years of service. McIlwraith is a Managing Director at Allos Ventures and has extensive experience in healthcare and technology sectors. His leadership is expected to enhance Meridian's innovation in diagnostics. Meridian is dedicated to developing diagnostic solutions and life science raw materials globally, serving various healthcare sectors.
Meridian Bioscience, Inc. (NASDAQ: VIVO) will report its first quarter 2022 financial results on February 4, 2022. CEO Jack Kenny will host a conference call at 10:00 a.m. Eastern Time to discuss the results. Investors can join the live call via webcast or by telephone. A replay will be available after the call. Meridian offers a range of diagnostic testing solutions and life science raw materials globally, serving various sectors including healthcare and environmental applications.
Meridian Bioscience, a leader in diagnostic testing, announced FDA clearance for its Curian® Campy assay on Jan. 5, 2022. This rapid test detects Campylobacter-specific antigens in fecal specimens, providing results in approximately 20 minutes. The assay enhances patient care by delivering accurate and timely results for campylobacteriosis, a common gastrointestinal infection. The Curian testing platform, which includes the newly cleared assay, aims to streamline testing in laboratories, following the prior clearance of the Curian HpSA® assay in March 2020.
Meridian Bioscience, a provider of diagnostic testing solutions, will participate in the 2022 H. C. Wainwright Bioconnect Virtual Conference. CEO Jack Kenny is set to pre-record a presentation available on January 10, 2022. The webcast can be accessed via Meridian's Investor Relations website, where it will remain available for 90 days. Meridian focuses on innovative diagnostics for various applications and serves clients in over 70 countries. The company's shares trade on NASDAQ under the symbol VIVO.
Meridian Bioscience, Inc. (NASDAQ: VIVO) announced the retirement of CFO Bryan Baldasare effective December 31, 2021. Baldasare, who joined the company in 2000 and became CFO in 2019, oversaw significant revenue growth exceeding 500% and global expansion during his tenure. Julie Smith has been appointed as Senior VP and principal accounting officer. The company is engaging an executive search firm for a new CFO. CEO Jack Kenny acknowledged Baldasare's substantial contributions and cited the strong finance organization left behind as a key asset for future continuity.